AR009069A1 - Arilalcanoilpiridazinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas - Google Patents

Arilalcanoilpiridazinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas

Info

Publication number
AR009069A1
AR009069A1 ARP970103679A ARP970103679A AR009069A1 AR 009069 A1 AR009069 A1 AR 009069A1 AR P970103679 A ARP970103679 A AR P970103679A AR P970103679 A ARP970103679 A AR P970103679A AR 009069 A1 AR009069 A1 AR 009069A1
Authority
AR
Argentina
Prior art keywords
atoms
pharmaceutical preparations
procedure
independently
hal
Prior art date
Application number
ARP970103679A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR009069A1 publication Critical patent/AR009069A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Se refiere a los derivados de la arilalcanoilpiridazina, de formula (I), en la que B es A, OA, NH2, NHA, NAA o un heterociclo insaturado con 1 a 4átomos de N, O y/o S, el cual puede no estar sustituido o estar mono, di o trisustituido con Hal, A y/o OA; Q está ausente o es alquileno de 1 a 6 átomosde C; R1, R2 son independientemente -OH, OR5, -SO-R5, -SO2-R5, Hal, -NO2, NH2, -NHR5 o -NR5R6; R1 y R2, juntos, también representan -O-CH2-O-; R3, R4 sonindependientemente H o A; R5, R6 son independientemente A, cicloalquilo de 3 a 7 átomos de C, metilencicloalquilo de 4 a 8 átomos de C o alquenilo de 2 a 8átomos de C; A, A son independientemente alquilo de 1 a 10 átomos de C, eventualmente sustituido con 1 a 5 átomos de F y/o Cl,y Hal es F, Cl, Br o I;y a sus sales aceptables desde el punto de vista fisiologico. Tambié se refiere a un procedimiento para preparar dichos compuestos, a preparacionesfarmacéuticas que los contienen y al empleo de los mismos para eltratamiento de la osteoporosis, los tumores, la aterosclerosis, la artritisreumatoidea, la esclerosis multiple, la diabetes mellitus, los procesos inflamatorios, las alergias, el asma, las enfermedades autoinmunes y los AIDS.Los nuevos compuestos presentan una accion inhibidora de la fosfodiesterasa IV.
ARP970103679A 1996-08-13 1997-08-13 Arilalcanoilpiridazinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas AR009069A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19632549A DE19632549A1 (de) 1996-08-13 1996-08-13 Arylalkanoylpyridazine

Publications (1)

Publication Number Publication Date
AR009069A1 true AR009069A1 (es) 2000-03-08

Family

ID=7802479

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970103679A AR009069A1 (es) 1996-08-13 1997-08-13 Arilalcanoilpiridazinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas

Country Status (24)

Country Link
US (1) US6479494B1 (es)
EP (1) EP0922036B1 (es)
KR (1) KR100554876B1 (es)
CN (1) CN1109022C (es)
AR (1) AR009069A1 (es)
AT (1) ATE262512T1 (es)
AU (1) AU725652B2 (es)
BR (1) BR9711066A (es)
CA (1) CA2263417C (es)
CZ (1) CZ291851B6 (es)
DE (2) DE19632549A1 (es)
DK (1) DK0922036T3 (es)
ES (1) ES2214633T3 (es)
HK (1) HK1021732A1 (es)
HU (1) HUP0001760A3 (es)
NO (1) NO312295B1 (es)
PL (1) PL331557A1 (es)
PT (1) PT922036E (es)
RU (1) RU2201923C2 (es)
SI (1) SI0922036T1 (es)
SK (1) SK282480B6 (es)
TW (1) TW427980B (es)
WO (1) WO1998006704A1 (es)
ZA (1) ZA977206B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19826841A1 (de) * 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine
DE19850701A1 (de) * 1998-11-04 2000-05-11 Merck Patent Gmbh Benzoylpyridazine
DE19915365A1 (de) * 1999-04-06 2000-10-12 Merck Patent Gmbh Tetrahydropyridazin-Derivate
DE19915364A1 (de) * 1999-04-06 2000-10-12 Merck Patent Gmbh Verwendung von Arylalkanoylpyridazinen
DE19932315A1 (de) * 1999-07-10 2001-01-11 Merck Patent Gmbh Benzoylpyridazine
JP5038568B2 (ja) 1999-08-21 2012-10-03 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 協力剤の組合せ物
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
DE10064997A1 (de) 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
WO2002072103A1 (en) * 2001-02-12 2002-09-19 Merck Patent Gmbh Use of type 4 phosphodiesterase inhibitors in myocardial diseases
JP2005515975A (ja) * 2001-10-31 2005-06-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ４型ホスホジエステラーゼ阻害剤およびこれらの使用
CN1585641A (zh) * 2001-11-05 2005-02-23 默克专利有限公司 亚肼基－丙二腈化合物
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
DE10225574A1 (de) * 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
DE10227269A1 (de) * 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
PL1954684T3 (pl) 2005-11-15 2014-10-31 Otsuka Pharma Co Ltd Związek oksazolowy i kompozycja farmaceutyczna
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7998971B2 (en) * 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650480B1 (en) * 1992-07-01 2001-11-21 Ortho Pharmaceutical Corporation 1-arylsulphonyl-3-phenyl-1,4,5,6-tetrahydropyridazines

Also Published As

Publication number Publication date
NO990676D0 (no) 1999-02-12
CN1227547A (zh) 1999-09-01
AU4013397A (en) 1998-03-06
DE59711450D1 (en) 2004-04-29
PT922036E (pt) 2004-06-30
US6479494B1 (en) 2002-11-12
NO312295B1 (no) 2002-04-22
NO990676L (no) 1999-02-12
CZ49399A3 (cs) 1999-05-12
CN1109022C (zh) 2003-05-21
KR100554876B1 (ko) 2006-02-24
HUP0001760A3 (en) 2001-07-30
KR20000029921A (ko) 2000-05-25
ES2214633T3 (es) 2004-09-16
TW427980B (en) 2001-04-01
WO1998006704A1 (de) 1998-02-19
ATE262512T1 (de) 2004-04-15
EP0922036B1 (de) 2004-03-24
JP4198755B2 (ja) 2008-12-17
PL331557A1 (en) 1999-07-19
CA2263417C (en) 2006-03-28
EP0922036A1 (de) 1999-06-16
CZ291851B6 (cs) 2003-06-18
SK282480B6 (sk) 2002-02-05
SK16899A3 (en) 1999-12-10
RU2201923C2 (ru) 2003-04-10
CA2263417A1 (en) 1998-02-19
DK0922036T3 (da) 2004-07-26
AU725652B2 (en) 2000-10-19
HUP0001760A2 (hu) 2001-05-28
BR9711066A (pt) 1999-08-17
DE19632549A1 (de) 1998-02-19
JP2001503022A (ja) 2001-03-06
SI0922036T1 (en) 2004-06-30
ZA977206B (en) 1999-11-12
HK1021732A1 (en) 2000-06-30

Similar Documents

Publication Publication Date Title
AR009069A1 (es) Arilalcanoilpiridazinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas
LU91145I2 (fr) FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX).
HUP9802630A2 (hu) Királis metil-fenil-oxazolidinonok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
SE9203825L (sv) Dubbelt verkande inhibitorer foer no-syntas och cyklooxygenas, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
IL123002A0 (en) 1-Phenyl-2- phenylacetoxy- ethanone derivatives
PT87474A (pt) Process for the preparation of pharmaceutical compounds which contain ester 1-acetoxi-ethylic of cefuroxime
RU95108329A (ru) Замещенные производные тиазолидиндиона, способ их получения, фармкомпозиция
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
HUP0100949A2 (hu) Aril kondenzált azapoliciklusos vegyületek és ezeket tartalmazó gyógyászati készítmények
TW369535B (en) A pyrazolopyridine compound and the process for preparing thereof
AR007828A1 (es) Compuestos derivados de piridilpirrol, procedimiento de preparacion y composiciones farmaceuticas conteniendo los mismos
PE32296A1 (es) Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables
HUP0001555A2 (hu) Tetrahidro-imidazo-naftiridin származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
ATE60579T1 (de) Pyrrolidinamid-derivate mit antipropylendopeptidase-wirkung, zusammenstellungen, die sie enthalten, verfahren zu ihrer herstellung und heilmittel, die sie enthalten.
AR021068A1 (es) Benzoilpiridazinas y procedimientos para elaborarlas; preparados farmaceuticos que las contienen y procedimiento para elaborarlos, y utilizacion de dichasbenzoilpiridazinas
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
ES2122637T3 (es) Derivados de tiazolidina, su preparacion y los medicamentos que les contienen.
AU638979B2 (en) New benzylcyclanone derivatives, process for preparing them and cosmetic and pharmaceutical compositions containing them
IL82084A0 (en) 1,4-diazepines,their preparation and pharmaceutical compositions containing them
HUP0002754A2 (hu) (1S,4R)-cisz-4-[2-amino-6-(ciklopropil-amino)-9H-purin-9-il]-2-ciklopentén-1-metanol-hemiszulfát, eljárás előállítására, ezt tartalmazó gyógyszerkészítmény, valamint intermedierek
FI881064A0 (fi) Menetelmä tulehduksenvastaisten tai analgeettisten -aminoetyylisubstituoitujen fenyyliyhdisteiden valmistamiseksi
AR005646A1 (es) Derivados de la quinolein-2-(1h)-ona, un procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos encalidad de medicamentos
FI883250A0 (fi) 3-desmetyl-4 -fluormevalonsyraderivat, foerfarande foer framstaellning av dem, pao dessa foereningar baserade farmaceutiska preparat, anvaendning av dem och mellanprodukter.
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
ES538982A0 (es) Procedimiento para obtencion de un preparado farmaceutico para tratamiento terapeutico de enfermedades reumaticas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal